Skorpios Trust Sells 1,937,500 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $12.86 on Wednesday. The stock has a market capitalization of $670.28 million, a price-to-earnings ratio of -5.34 and a beta of 0.96. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $17.58. The company has a 50 day moving average price of $14.44 and a 200 day moving average price of $13.28.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The business had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. On average, sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Institutional Trading of Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC acquired a new position in shares of Stoke Therapeutics in the second quarter worth about $29,000. Nisa Investment Advisors LLC raised its holdings in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at approximately $123,000. State Board of Administration of Florida Retirement System acquired a new position in Stoke Therapeutics in the 1st quarter worth approximately $141,000. Finally, The Manufacturers Life Insurance Company grew its position in Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after purchasing an additional 1,994 shares in the last quarter.

Wall Street Analysts Forecast Growth

STOK has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Wedbush reaffirmed an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.